>
-Berry Declares Quarterly Dividend-Resumen: Precisely refuerza su oferta de Location Intelligence con la adquisición de Transerve-Curative Insurance Company’s Financial Strength Affirmed with A- (Excellent) Rating from AM Best and Infusion of $100 Million Demonstrates Curative’s Long-Term Commitment to Its Innovative Health Plan-Riveron Study Reveals Optimistic Outlook for Corporate Development in 2023-Stewart Information Services Corporation Announces Fourth Quarter 2022 Earnings Conference Call-Lake Shore Bancorp, Inc. Announces Full Year 2022 and Fourth Quarter Financial Results-Allied Announces Fourth-Quarter and Year-End Results-QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNINGS-Fidus Investment Corporation Announces Deemed Distribution of $1.65 per Share and U.S. Federal Income Tax Treatment of 2022 Dividends-Global Insulated Gate Bipolar Transistor [IGBT] Market Size To Grow USD 10 Billion By 2030 | CAGR 9%-U.S. Physical Therapy, Inc. Schedules Fourth Quarter and Year Ended 2022 Earnings Release and Conference Call-CRCAM Alpes Provence : mise à disposition de l’Avis financier au 31 décembre 2022-CRCAM Alpes Provence : Avis financier au 31 décembre 2022-Global Silicone Polymer Market Size To Surpass $35.90 Billion By 2030 | CAGR 6.4%-Crédit Agricole Brie Picardie : Résultats financiers au 31 décembre 2022-Alchimie Has Successfully Completed the First Phase of Its Transition and Announces 2022 Sales of €22 Million and the Achievement of Operational Profitability-Global Wireless Sensors Market Size To Grow USD 149 Billion By 2030 | CAGR of 19%-Global Radar Sensor Market Size To Grow USD 43.5 Billion By 2030 | CAGR 18.6%-Global Digital TV SoC Market Is Expected to Reach $28.2 Billion by 2031: Says AMR-Global Top 6 Agriculture Equipment Manufacturers Strategic Analysis Report 2022-2023: OEM's Strategic Positioning and its Degree of Responsiveness to Internal & External Factors – ResearchAndMarkets.com

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON–()–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,000 shares of Astria’s common stock on December 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to an employee or employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.00, which is equal to the closing price of Astria’s common stock on December 1, 2022 (the “Grant Date”), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee’s employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee’s continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

Leave a Comment